Abstract：
OBJECTIVE: Evaluate surgical utilization of SCOUT reflectors placed at breast biopsy.
METHODS: Consent was waived for this retrospective IRB-approved, HIPAA-compliant study. Breast biopsy examinations that reported the term \"SCOUT\" between January 2021 and June 2022 were identified using an institutional search engine. Cases were included if a SCOUT reflector was placed at time of breast biopsy and excluded if lesion pathology was already known. Analysis was performed at the lesion level. A multivariate-regression analysis evaluated 6 variables with potential impact on SCOUT utilization.
RESULTS: One hundred twenty-one lesions in 112 patients met inclusion criteria. Biopsy yielded 93% (113/121) malignant, 3% (4/121) elevated risk, 2% (2/121) benign-discordant, and 2% (2/121) benign-concordant results. Two cases lost to follow-up were excluded. SCOUT reflectors were utilized for lumpectomy (58%, 69/119 lesions) and excisional biopsy (6%, 7/119 lesions). SCOUTs were not utilized due to mastectomy (23%, 27/119), subsequent wire localization (2%, 2/119), and nonsurgical cases (12%, 14/119). Reflector placement utilization was 52% higher for findings less than 3.5 cm in size (P <.001), 33% higher in patients without prior treated breast cancer (P = .012), and 19% higher in patients with no suspicious ipsilateral lymph node (P = .048).
CONCLUSIONS: SCOUT reflector placement at time of biopsy was utilized for surgery 64% (76/119) of the time, although most (98%, 119/121) biopsies were malignant, elevated risk, or benign-discordant. Factors increasing reflector utilization include smaller lesion size, no suspicious ipsilateral lymph node, and no prior treated breast cancer.
METHODS: Consent was waived for this retrospective IRB-approved, HIPAA-compliant study. Breast biopsy examinations that reported the term \"SCOUT\" between January 2021 and June 2022 were identified using an institutional search engine. Cases were included if a SCOUT reflector was placed at time of breast biopsy and excluded if lesion pathology was already known. Analysis was performed at the lesion level. A multivariate-regression analysis evaluated 6 variables with potential impact on SCOUT utilization.
RESULTS: One hundred twenty-one lesions in 112 patients met inclusion criteria. Biopsy yielded 93% (113/121) malignant, 3% (4/121) elevated risk, 2% (2/121) benign-discordant, and 2% (2/121) benign-concordant results. Two cases lost to follow-up were excluded. SCOUT reflectors were utilized for lumpectomy (58%, 69/119 lesions) and excisional biopsy (6%, 7/119 lesions). SCOUTs were not utilized due to mastectomy (23%, 27/119), subsequent wire localization (2%, 2/119), and nonsurgical cases (12%, 14/119). Reflector placement utilization was 52% higher for findings less than 3.5 cm in size (P <.001), 33% higher in patients without prior treated breast cancer (P = .012), and 19% higher in patients with no suspicious ipsilateral lymph node (P = .048).
CONCLUSIONS: SCOUT reflector placement at time of biopsy was utilized for surgery 64% (76/119) of the time, although most (98%, 119/121) biopsies were malignant, elevated risk, or benign-discordant. Factors increasing reflector utilization include smaller lesion size, no suspicious ipsilateral lymph node, and no prior treated breast cancer.
摘要：
目的：评估放置在乳腺活检中的SCOUT反射器的手术利用率。
方法：放弃了对该回顾性IRB批准的同意，符合HIPAA的研究。在2021年1月至2022年6月之间报告术语“SCOUT”的乳腺活检检查是使用机构搜索引擎确定的。如果在乳腺活检时放置SCOUT反射器，则包括病例，如果病变病理已知，则排除病例。在损伤水平进行分析。多元回归分析评估了6个对SCOUT利用率有潜在影响的变量。
结果：112例患者中有121个病灶符合纳入标准。活检产生93%（113/121）恶性，3%(4/121)风险升高，2%(2/121)良性不一致，和2%(2/121)的良性一致结果。排除2例失访病例。SCOUT反射器用于肿块切除术(58%，69/119个病灶）和切除活检（6%，7/119个病变）。由于乳房切除术，未使用SCOUT(23%，27/119),后续导线定位(2%，2/119),和非手术病例(12%，14/119)。对于尺寸小于3.5厘米的发现，反射器放置利用率高出52%(P<.001)，没有接受过治疗的乳腺癌患者高出33%（P=0.012），无可疑同侧淋巴结的患者高19%(P=0.048)。
结论：活检时的SCOUT反射器放置用于64％（76/119）的手术时间，虽然大多数（98%，119/121）活检为恶性，风险升高，或者良性不和谐。增加反射器利用率的因素包括较小的病变大小，没有可疑的同侧淋巴结，之前没有治疗过的乳腺癌.
方法：放弃了对该回顾性IRB批准的同意，符合HIPAA的研究。在2021年1月至2022年6月之间报告术语“SCOUT”的乳腺活检检查是使用机构搜索引擎确定的。如果在乳腺活检时放置SCOUT反射器，则包括病例，如果病变病理已知，则排除病例。在损伤水平进行分析。多元回归分析评估了6个对SCOUT利用率有潜在影响的变量。
结果：112例患者中有121个病灶符合纳入标准。活检产生93%（113/121）恶性，3%(4/121)风险升高，2%(2/121)良性不一致，和2%(2/121)的良性一致结果。排除2例失访病例。SCOUT反射器用于肿块切除术(58%，69/119个病灶）和切除活检（6%，7/119个病变）。由于乳房切除术，未使用SCOUT(23%，27/119),后续导线定位(2%，2/119),和非手术病例(12%，14/119)。对于尺寸小于3.5厘米的发现，反射器放置利用率高出52%(P<.001)，没有接受过治疗的乳腺癌患者高出33%（P=0.012），无可疑同侧淋巴结的患者高19%(P=0.048)。
结论：活检时的SCOUT反射器放置用于64％（76/119）的手术时间，虽然大多数（98%，119/121）活检为恶性，风险升高，或者良性不和谐。增加反射器利用率的因素包括较小的病变大小，没有可疑的同侧淋巴结，之前没有治疗过的乳腺癌.
